CHAIN has been awarded £0.5M grant funding from Innovate UK, the UK’s Innovation agency, to expand its range of biotechnology products. Building on a successful synthetic biology program, the grants support further development of CHAIN’s proprietary Clostridium platform for therapeutic and specialty chemical applications. A two-year project will focus on the development of novel therapeutics […]
CHAIN plans to attend a record number of microbiome and biotech conferences over the next year to showcase our therapeutic platform and identify partners for the development of novel, targeted therapies. First up is the Spores Conference in April where our Technical Product Manager, Dr Daniela Heeg, will speak about CHAIN’s novel therapeutic delivery platform. […]
CHAIN are excited to announce the launch of our re-designed website. The new look features a sleek design optimised for mobile and tablet readers to showcase our novel technology platform and how microbiome therapy. In addition to our main site, we now have an e-shop for customers to purchase molecular biology tools and strains. Microbiome […]
CHAIN Biotechnology Ltd develops Clostridium-based microbial technology for high-value healthcare products. We produce novel 2nd generation live biotherapeutic products for chronic gut-related diseases.
CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD™ technology. Our lead product targets Inflammatory Bowel Disease.